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Abstract 
Cell transplantation studies of spinal cord injury have a premise that the transplants hould 
be integrated in the host spinal cord tissue, differentiate into neural cells, and re-establish 
neural circuits, leading to the improvement of locomotor functions. However, the long-
term survival, extensive proliferation, and/or differentiation of transplanted cells are not 
necessarily desirable clinically, and may, on the contrary, cause serious problems regarding 
the safety of transplants. The excessive proliferation, migration, and/or differentiation of 
transplanted cells may deteriorate the histological as well as functional organization of the 
host spinal cord. The present communication will discuss the feasibility of using three 
kinds of cell as transplants, including bone marrow-derived cells (BMDCs), Schwann cells, 
and neural stem/progenitor cells (NSPCs). 
BMDCs enhance tissue recovery and locomotor improvements ; however, they disappear 
within 2-3 weeks after transplantation from the host spinal cord. This indicates that 
BMDCs do not serve as scaffolds for the growth of regenerating axons, but promote  
"  
endogenous" regenerating capacities of the host spinal cord, probably by secreting some 
trophic factors. This short-term survival of transplants, although appearing to be a 
disadvantage, guarantees the safety of cell transplantation. The transplantation of BMDCs 
is now at the Phase  I/II stage of clinical application. 
Schwann cells have been studied extensively as a transplant material for spinal cord injury. 
Schwann cells survive long-term, and moderately proliferate and/or migrate in the spinal 
cord. It can be said that Schwann cells become well integrated in the host spinal cord. 
Therefore, they are regarded as a safe transplant. 
NSPCs proliferate, migrate, and differentiate xtensively after transplantation in the host 
spinal cord. It is impossible at present to manipulate or control the proliferation/ 
migration/differentiation of NPSCs to make them properly integrate in the host spinal 
cord. NSPCs are not considered safe for clinical application. BMDCs and Schwann cells 
are clinically relevant, while NS/PCs are clinically irrelevant.
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 Abbreviations  :
BDNF : brain-derived neurotrophic factor, BMDC : bone marrow-derived cell,  BMNC  : 
bone marrow mononuclear cell, BMSC : bone marrow stromal cell, CNS : central nervous 
system, CPC : cell-processing center, CPEC : choroid plexus epithelial cell,  CSF  : 
cerebrospinal fluid, EGF : epidermal growth factor, ES : embryonic stem, FGF : fibroblast 
growth factor, GFAP : glio-filament-associated protein, GDNF : glial cell line-derived 
neurotrophic factor, GGF : glial growth factor, HGF : hepatocyte growth factor,  IGF  : 
insulin-like growth factor, iPSC : induced pluripotent stem cell, NSPC : neural stem/ 
progenitor cell, SCI : spinal cord injury, TNF : tumor necrosis factor, NT-3 : neurotropin -3, 
OEC : olfactory ensheathing cell, PDGF : platelet-derived growth factor
Introduction
 Many kinds of cell, such as bone marrow-
derived cells (BMDCs) that include bone marrow 
stromal cells (BMSCs) and bone marrow mono-
nuclear cells (BMNCs), Schwann cells, olfactory 
ensheathing cells (OECs) (Li et al., 1998), adipose-
derived stem cells (Arboleda et al., 2011), skin-
derived stem cells (Biernaskie et al., 2007), 
umbilical cord-derived stem cells (Yang et al., 
2008), dental pulp-derived stem cells (Sakai et al., 
2012), choroid plexus epithelial cells (CPECs) 
(Kanekiyo et al., 2015), and neural stem/projector 
cells (NSPCs), have been studied as transplants in 
experimental studies for the treatment of spinal 
cord injury. 
 NSPCs are derived from the embryonic/ 
newborn CNS, induced pluripotent stem cells 
(iPSCs), or embryonic stem (ES) cells. All other 
cells are derived from adult somatic or umbilical 
tissues : BMDCs and adipose- and umbilical-
derived stem cells can be categorized as mesen-
chymal stem cells, while Schwann cells, OECs, and 
CPECs belong to the peripheral or central 
nervous system. 
 BMDCs, Schwann cells, and OECs have been 
studied extensively with promising results, and 
are now at the Phase  I/II stage of clinical appli-
cation. On the other hand, NSPCs have serious 
problems regarding clinical application. NSPCs 
derived from ES cells have ethical problems, and 
those derived from iPSCs have tumorigenic 
problems. NSPCs survive long-term, proliferate, 
and differentiate into neural cells such as neurons 
and glial cells, after transplantation. These pro-
perties, although appearing favorable for 
transplant materials, pose critical problems in 
clinical application. 
 The present communication deals with three 
kinds of  cell  : BMDCs and Schwann cells as 
somatic cells, and NSPCs as embryonic/artificially 
manipulated stem cells. We discuss their positive 
and/or negative properties of them from the point 
of view of transplant safety.
 We believe that the cell transplantation studies 
aiming at the regeneration of tissues or organs 
have significance only when they are clinically 
applicable under the condition that the trans-
plants are safe and they promote functional 
improvements of recipients.
 I. BMDCs
 BMDCs include BMSCs and BMNCs. BMSCs 
are cells that adhere to the dish in cell culture of 
bone marrow perfusate. BMMCs are nucleated 
cells obtained without culture after erythrocytes 
are removed from the bone marrow perfusate. 
 The effects of BMSCs on the repair of an 
injured spinal cord and locomotor improvement 
were studied by Ohta et al. (2004). This pio-
neering work adopted a new method for cell 
transplantation : BMSCs were infused through 
the 4th ventricle into the CSF. The cell infusion 
was done immediately after contusion injury of 
the spinal cord. Infused cells, after flowing 
through the CSF, attached to the surface of the 
spinal cord, some of which invaded the spinal cord 
lesion. These cells disappeared before 3 weeks 
after infusion from the spinal cord. Locomotor 
functions were clearly improved, and cavity 
formation in the spinal cord lesion was sup-
pressed. It was suggested that host spinal cord 
axons near the lesion did not undergo  secondary 
degeneration, but were spared in BMSC-
transplanted rats. These findings indicate that 
BMSCs did not serve as a scaffold of regenerating 
axons, but probably released some trophic factors, 
which were effective for tissue repair, and axonal 
outgrowth and preservation, in the spinal cord 
injury. 
 This study opens up a new field for the treat-
ment of spinal cord injury : BMSCs are safe and 
effective transplants, because they do not survive 
long-term in the spinal cord, while enhancing 
locomotor recovery. In addition, the transplan-
tation of BMSCs through the CSF means that the 
lumbar puncture technique can be used for cell
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transplantation in clinical usages. 
 In the next study, we injected BMSCs directly 
into the spinal cord lesion 2 weeks after injury 
(subacute spinal cord injury, Ide et al., 2010). 
Transplanted BMSCs survived as cell assemblies 
for 1-2 weeks in the lesion, which remained as an 
astrocyte-devoid area, appearing as empty 
cavities on immunostaining for GFAP. However, 
it was found that such astrocyte-devoid spaces are 
filled with extracellular matrices including 
collagen fibers. Numerous axons associated with 
Schwann cells grew out through such extra-
cellular matrices in astrocyte-devoid areas (Fig. 1). 
These axons were myelinated by Schwann cells,
displaying peripheral nerve-like structures. This 
indicated that these axons might not be spared 
ones, but regenerated ones in the spinal cord 
lesion. There was no finding indicating the 
blocking of axonal extension at the border of the 
lesion. No astrocytic scar was formed at the 
border. Cavity formation was reduced in cell-
transplanted rats. Locomotor behavior improved 
to 9-10 points as assessed by the BBB scale, while 
it remained at 5-6 points in the control. This 
study demonstrated that, BMSCs, even though 
they disappeared 1-2 weeks after transplantation, 
promoted axonal regeneration and locomotor 
improvement, probably by secreting some trophic
Fig.  1 The spinal cord was contusion-injured at T8-9 in adult rats, and BMSCs were 
transplanted into the spinal cord lesion at 2 weeks  post-injury. Rats were fixed at 1 week 
post-transplantation, and horizontal sections of the spinal cord lesion were observed. 
Left to right : rostro-caudal direction.  a-1 : HE staining. The lesion is filled with tissue (S) 
different from the spinal cord parenchyma (H). An asterisk indicates the site of engrafted 
BMSCs shown in a-2. a-2 : The section adjacent o  a-1. Engrafted BMSCs are found as 
cell assemblies  (*). a-3 : GFAP immunohistochemistry (red) in the section adjacent to 
a-2. A large astrocyte-devoid area (S) extends rostro-caudally. Engrafted BMSCs (site 
indicated by asterisk) are located at the border of the astrocyte-devoid  area  a-4  : 
Immunohistochemistry for neurofilaments in the section adjacent to a-3. Numerous 
axons (red) extend in a bundle along the total length of the astrocyte-devoid area shown 
in a-3. Numerous regenerating axons extend through the lesion of the spinal cord injury. 
There is no finding suggesting the blocking of extension of growing axons at the 
transition zones (arrows) on the rostral or caudal side. The asterisk indicates the site of 
engrafted BMSCs. H shows spinal cord  parenchyma. Scale : 2 mm 
From Ide et al.  (2010).
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factors. 
 We further advanced the experiment : BMSCs 
were infused through the CSF three times (once 
weekly) in subacute (1 and 2 weeks after injury) 
and chronic (4 weeks after injury) groups (Nakano 
et al., 2013). Similar to a preceding study (Ide et 
al., 2010), numerous axons associated with 
Schwann cells extended through the extracellular 
matrices (connective tissues) in the astrocyte-
devoid areas of the spinal cord lesion. In the  1-
week post-injury group, a small number of BMSCs 
were found to have survived at 2 days after 
injection within the spinal cord lesion, but none 
were found at 7 days. No BMSCs were found in 
the spinal cord lesion 2 or 7 days after injection in 
the 2- or 4-week post-injury groups. In all 3 
groups, BBB scores increased from 1-4 points 
before injection to  9-11 points at 4 weeks after the 
initial injection, while they increased only slightly 
from 1-4 to 3-5 points in the control. These 
findings indicate that, like in the preceding study, 
BMSCs exerted their effects not by serving as 
scaffolds for regenerating axons, but by secreting 
trophic factors effective for the regeneration and 
extension of axons in the spinal cord lesion. 
 It should be noted that, even in the control 
group, there were a few regenerating axons 
extending through the astrocyte-devoid area. 
This indicates that the spinal cord has 
 "  
endogenous" abilities to repair the lesion by 
forming extracellular matrices, through which 
regenerating axons extend. 
 In addition to the study of BMSC trans-
plantation, we studied the transplantation of 
BMNCs in rats with SCI (Yoshihara et al., 2007). 
Mononuclear cells were separated from bone 
marrow infusate by density-gradient centri-
fugation. The separated cells include those that 
are positive for  CD90  (Thy-1), CD45 (for 
leukocytes), CD29  ( 1-integrin), CD  117 (c-kit), 
CD34 (for hematopoietic stem cells),  CD31 (for 
endothelial cells) and  CD11/b (for macrophages). 
One hour after contusion injury of the spinal cord, 
a cell suspension was injected into the 4th 
ventricle. Injected cells were found in the choroid 
plexus and on the spinal cord surface at 3 days, 
but were no longer observed at 7 days after 
transplantation. The BBB scores increased to 15 
points at 5 weeks post-transplantation, while they 
were  10 points in the control. 
 Cavity formation was suppressed and blood 
vessel formation was promoted. 
 Regenerating axons were observed within the 
lesion. The CSF harvested 3 days after cell 
infusion showed increased HGF and decreased
 TNF- . BMNCs disappeared before 7 days post-
transplantation. These findings indicate that 
BMNCs might release some trophic factors into 
the CSF, leading to axonal regeneration, blood 
vessel formation, and the suppression of cavity 
formation. 
 Based on these studies, we advanced to the 
clinical application of BMSCs for patients with 
SCI. The fact that BMSCs do not survive long-
term to be integrated into the host tissue, but they 
still promote the locomotor function and axonal 
regeneration, indicate that they are safe and 
effective as transplants for the treatment of SCI. 
The first transplantation to a patient was 
performed in 2006 (Saito et al., 2008), and a total of 
5 patients received BMSC transplantation up until 
2009 (Saito et al., 2012). To our knowledge, the 
patient who received BMSCs in 2006 was the first 
case of BMSC transplantation for spinal cord 
injury in Japan. Cell transplantation was per-
formed by lumbar puncture in all 5 patients. 
There was no adverse effect, and patients showed 
varying levels of recovery in locomotor and 
sensory functions, revealing that the trans-
plantation of BMSCs by lumbar puncture is 
promising for the treatment of patients with SCI. 
 We advanced to the use of BMNCs for clinical 
application. BMNCs do not need to be cultured 
before transplantation. This is an advantage of 
BMNCs over BMSCs. BMNCs can be separated 
immediately after obtaining them from the iliac 
bone of the patient, and transplanted by lumbar 
puncture without culturing in an expensive Cell 
Processing Center (CPC). So far, 10 patients have 
received BMNC transplantation by lumbar punc-
ture. Six months after transplantation, patients 
were assessed regarding sensory and motor 
functions. There was no adverse effect in any of 
the  10 patients. Patients showed varying degrees 
of improvement in motor, light touch, and pin 
prick scores (Suzuki et al.,  2014). This was a 
pioneering study showing that the BMNC 
transplantation by lumbar puncture is effective 
and feasible for patients in a hospital with no CPC 
facilities. BMNCs are promising for the treat-
ment of patients with SCI.
2. Schwann cells
 Since the epoch-making, elegant study by David. 
and Aguayo  (1981) demonstrated that trans-
planted peripheral nerve segments provide a 
favorable environment for the growth of 
regenerating axons in the CNS, Schwann cells 
have been regarded as a key cell to provide an
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appropriate environment for the growth of 
regenerating axons in the CNS. They showed 
that Schwann cells also worked as scaffolds for 
the growth of regenerating axons also in the 
central nervous system, indicating that Schwann 
cells may be effective transplants for spinal cord 
injury. Since then, many studies have been 
performed using Schwann cells as transplants to 
promote nerve regeneration in the spinal cord 
injury (William and Bunge, 2012). 
 Schwann cells were obtained from adult  peri-
pheral nerves. Small nerve explants were 
allowed to undergo axonal and myelin breakdown, 
and enzymatically dissociated. Dissociated 
Schwann cells were treated with glial growth 
factor (GGF) and forskolin, and cultured for 10 
weeks. Thus, Schwann cells were derived from 
the adult nerves with no genetic manipulation. 
 The problem with Schwann cells is that regen-
erating axons growing through the assemblies of 
transplanted Schwann cells do not exit the 
transplants in the spinal cord lesion (Kanno et al., 
2015). It is assumed that axons are blocked from 
extending through the glial scar formed at the 
border of the lesion. It is considered that 
chondroitin sulfate in the scar tissue inhibits the 
growth of regenerating axons. This disadvantage 
was overcome through the digestion of 
chondroitin sulfate by chondroitinase ABC (Chau 
et al., 2003), by the local injection of growth factors 
(aFGF, GDNF), and/or co-transplantation of 
Schwann cells with other types of cells such as 
BMDCs, OECs, and NSPCs (Deng et al., 2015). 
 It was shown that "modified" or  "  activated" 
Schwann cells that were generated at the 
proximal as well as distal stumps of transected 
peripheral nerves have beneficial effects on 
axonal regeneration, when transplanted in the 
spinal cord lesion (Senoo et al., 1998). 
 It was reported that  60-90%of the transplanted 
Schwann cells survived over 3 weeks after trans-
plantation (Pearse and Bunge 2007). Schwann cell 
proliferation peaked at 2 weeks, decreased there-
after, and ceased at 12 weeks  post-transplan-
tation. Some Schwann cells had migrated along 
the central canal for up to 5 mm at 4 weeks post-
grafting (Wang and Xu, 2014). 
  Schwann cells show moderate proliferation and 
migration, but no differentiation after transplan-
tation. Schwann cells are well integrated in the 
host spinal cord tissue. Therefore, they are 
considered safe as transplants, and available for 
clinical applications. 
  It was reported that there was a marked 
infiltration of endogenous Schwann cells into the
host spinal cord tissue (Hill et al., 2006). This 
finding is in line with that of our study that 
regenerated axons are surrounded by Schwann 
cells in the BMSC transplantation. This finding 
poses the question of how many transplanted 
Schwann cells contribute to myelin sheath 
formation in the host spinal cord lesion. Schwann 
cells surrounding regenerating axons in the 
Schwann cell-transplanted spinal cord are pre-
sumably a mixture of transplanted and endoge-
nous ones. 
 Functional recovery after Schwann cell trans-
plantation was not so prominent in rats with SCI 
(Wang and Xu, 2014).
3. Neural stem cells
 In our previous study, NSPCs were obtained 
from the fetal central nervous system, and 
injected into the spinal cord lesion (Wu et al., 
2001). NSPCs survived, effectively integrated, 
and migrated extensively. They were differen-
tiated into neurons and astrocytes by 4 weeks 
post-transplantation. NSPCs were suggested to 
be a potent, promising candidate in cell trans-
plantation for SCI. When they were transplanted 
through the CSF (Wu et al., 2002), NSPCs attached 
to the surface of the intact as well as injured spinal 
cord, and migrated into the spinal cord tissue. 
These findings were interesting from the point of 
view of basic science ; however, we wondered at 
that time whether NSPCs with the potent 
properties of migration and proliferation were 
safe as transplants from a clinical point of view. 
Are NSPCs applicable for clinical cases ? For 
further examination, NSPCs obtained from the 
fetal hippocampus were infused into the CSF. 
NSPCs attached to the surface of the spinal cord, 
proliferated, and occupied a large area of the 
spinal cord 3 weeks after transplantation (Bai et 
al., 2003) (Fig. 2). They survived long-term, and 
proliferated and migrated extensively. From 
these findings, we thought that NSPCs were not 
safe as transplants from a clinical point of view. 
As stated above, we think that regeneration 
studies are of significance only when they can be 
applied clinically. Therefore, we discontinued the 
study of NSPCs as transplants for spinal cord 
injury. 
 Lu et al. (2012) reported a study using NSPCs 
derived from ES cells for spinal cord injury in rats. 
NSPCs were suspended in a  fibrin matrix  con-
taining growth factors such as BDNF, NT-3, 
PDGF, IGF, EGF, bFGF, aFGF, GDNF, and HGF. 
This mixture of NSPCs and growth factors was
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Fig. 2 Neurospheres were formed by culturing dissociated hippocampal cells of E16 fetuses of 
GFP-transgenic rats. Neurospheres containing NSPCs were injected into the CSF via the 4th 
ventricle of normal, intact rats. This micrograph shows the whole view of thoracic segments of 
spinal cords at 3 (A), 5 (B), 7 (C), 14 (D), and 21 days  (E) after cell injection. Pictures in the left 
column show the dorsal surface, and those in the right column show the ventral surface of the 
spinal cord. GFP-labeled NSPC clusters attached to the spinal cord surface, and increased 
gradually to cover a large area of the spinal cord surface at 3 weeks after cell injection. NSPCs 
will continue to proliferate to cover the entire surface of the spinal cord. NSPC clusters were 
formed around blood vessels (*), and further expanded over them (arrows). Scale : 2.0 mm 
From Bai et al. (2003).
injected into the transected lesion at T3, and 
observed for 7 weeks after transplantation. 
Transplanted NSPCs survived, and filled the 
spinal cord lesion. They differentiated into astro-
cytes and neurons. NSPC-derived neurons ex-
tended axons over a long distance up to C8 rostal 
and  Ll caudal to the T3 site. Axons were 
myelinated, and formed synapses with host 
neurons. In a re-examination of this study, Sharp 
et al.  (2014) stated that the transected lesion of the 
spinal cord remained as a partition, and there was 
no ingrowth of host axons into the transplants of 
NSPCs. There was no functional recovery. 
 In another paper, Lu et al.  (2014) used human 
iPSC-derived NSPCs as transplants. The spinal 
cord was transected at C5, and NSPCs in fibrin 
matrices containing a growth factor cocktail, as 
described above, were transplanted 2 weeks after 
transection. Observation was performed 3 
months after transplantation. NSPCs filled the 
lesion cavities, differentiated into neurons, and 
extended numerous axons rostrally up to the 
midbrain and even to the cortex. Many axons also 
extended caudally up to T6, or even to the  T12 
level. No myelination was noted on regenerated
axons extending through the white matter of the 
host spinal cord. No functional recovery was 
observed. 
 Concerning  "safe" and  "unsafe iPSCs, NSPCs 
derived from murine iPSCs were transplanted 
into the spinal cord lesion of mice. NSPCs 
differentiated into neurons, astrocytes, and 
oligodendrocytes. Oligodendrocytes formed a 
myelin sheath on axons. No tumor formation was 
found on the transplantation of NSPCs derived 
from "safe" iPSCs for 5 weeks post-trans-
plantation, whereas those derived from "unsafe" 
iPSCs showed robust teratoma formation (Tsuji et 
al.,  2010). It is impossible to evaluate the safety of 
NSPCs in such short a time as 5 weeks post-
transplantation. The functional recovery was not 
so marked as to offset the concern about the 
tumorigenicity of iPSC-derived NSPCs. 
 Concerning the risk of the tumorigenicity of 
iPS-derived NSPCs, the ablation of tumors was 
studied through immunoregulation. NSPCs  deriv-
ed from  tumorigenic iPSCs were transplanted into 
the intact spinal cords of immunocompetent mice 
with or without immunosuppressant treatment. 
All transplants survived in the group receiving
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immunosuppressant treatment. Most of  them 
developed tumors at 3 months after trans-
plantation. Tumors were rejected within 42 days 
after the discontinuation of immunosuppressants. 
The authors concluded that the immune rejection 
could be used as a "fail-safe" system against 
potential tumorigenicity after the transplantation 
of iPSC-derived NSPCs to treat SCI (Itakura et al., 
2015). This study clearly shows the risk of iPSC-
derived NSPCs for spinal cord injury. For the use 
of iPSC-derived NSPCs a high hurdle must be 
overcome before they can be applied as a 
transplant for spinal cord injury clinically. Simil-
arly, tumor formation was reported in 103 days 
after the transplantation of human iPSC-derived 
NSPCs  (Nori et al., 2015). 
 Lee-Kubli and Lu (2015) observed that iPSC-
derived NSPCs grew out axons extensively, 
resulting in the innervation of ectopic targets. 
They thought that ectopic innervations could 
potentially be manipulated and shaped with axon-
guidance strategies. In addition, cell proliferation, 
migration, and differentiation should be appro-
priately manipulated in clinical application. At 
present, however, there is no effective method to 
manipulate/control the ectopic innervation, pro-
liferation, migration, and differentiation of NSPCs 
in spinal cord lesions. Lee-Kubli and Lu (2015) 
stated as follows : "Ideal methods of iPSC re-
programming and differentiation remain to be 
developed for clinical translation, and further 
experimentation is necessary at the pre-clinical 
 level." Mothe and Tator (2013) stated that "NSPCs 
are multipotent cells that  self-renew and are 
committed to the neural lineage, and thus, they 
are especially suited to SCI repair. NSPCs may 
differentiate into neural cells after transplantation 
into injured spinal cord, replace lost or damaged 
cells, providing trophic support, restoring 
connectivity and facilitating  regeneration." This 
view of NSPCs is too optimistic. This statement 
means that NSPCs cannot be used for clinical 
purposes until the methods are developed, by 
which the behaviors of NSPCs can be properly 
manipulated and controlled. 
 Locomotor recovery is the essential parameter 
for the clinical application of cell transplantation. 
The critical problem is that NSPC transplantation 
is not necessarily effective for locomotor im-
provement. NSPCs will remain irrelevant clini-
cally until their proliferation, migration, differen-
tiation, and axonal extension can be effectively 
controlled for the safety of recipients.
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